CD263 (TRAIL-R3) Monoclonal Antibody (DJR3), PE, eBioscience™, Invitrogen™

Description

• Description: The DJR3 monoclonal antibody reacts with human Decoy receptor 1 (DcR1), a glycophospholipid-anchored cell surface protein also known as TRAIL-R3, TRID, and LIT
• DcR1 has an extracellular TRAIL binding domain and lacks the cytoplasmic death domain (DD) shared by several members of the TNF receptor superfamily
• DcR1, along with DcR2, protects cells from TRAIL-mediated cytotoxicity
• DcR1 binds to TRAIL and inhibits binding of TRAIL to DR4 or DR5
• DcR1 is expressed broadly in many normal tissues at low level, but not in most tumors
• Overexpression of DcR1 attenuates TRAIL-induced apoptosis
• Applications Reported: The DJR3 antibody has been reported for use in flow cytometric analysis
• Applications Tested: This DJR3 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells and human DcR1-transfected cells
• This can be used at 5 μL (1 μg) per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser
• Filtration: 0.2 μm post-manufacturing filtered
• TRAIL-R3 (CD263) is a member of the TNF-receptor superfamily
• This receptor contains an extracellular TRAIL-binding domain and a transmembrane domain, but no cytoplasmic death domain
• This receptor is not capable of inducing apoptosis, and is thought to function as an antagonistic receptor that protects cells from TRAIL-induced apoptosis
• This gene was found to be a p53-regulated DNA damage-inducible gene
• The expression of this gene was detected in many normal tissues but not in most cancer cell lines, which may explain the specific sensitivity of cancer cells to the apoptosis-inducing activity of TRAIL.